Traditional Vitamin D Therapy + Cinacalcet

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Hyperparathyroidism, Secondary

Conditions

Hyperparathyroidism, Secondary

Trial Timeline

Oct 1, 2010 → Aug 14, 2012

NCT ID

NCT01181531

About Traditional Vitamin D Therapy + Cinacalcet

Traditional Vitamin D Therapy + Cinacalcet is a approved stage product being developed by Amgen for Hyperparathyroidism, Secondary. The current trial status is completed. This product is registered under clinical trial identifier NCT01181531. Target conditions include Hyperparathyroidism, Secondary.

What happened to similar drugs?

12 of 20 similar drugs in Hyperparathyroidism, Secondary were approved

Approved (12) Terminated (2) Active (8)

✅Cinacalcet HClKyowa KirinApproved

✅Paricalcitol + CalcifediolAbbVieApproved

✅Paricalcitol + Darbepoetin alfaAbbVieApproved

✅Alendronate 70mg weeklyMerckApproved

✅AMG 073AmgenApproved

✅DenosumabAmgenApproved

✅Sensipar® + Vitamin DAmgenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01181531	Approved	Completed	Oct 1, 2010	Aug 14, 2012	Hyperparathyroidism, Secondary

Competing Products

20 competing products in Hyperparathyroidism, Secondary

See all competitors

Product	Company	Stage	Hype Score
ASP7991 + Cinacalcet + Placebo	Astellas Pharma	Phase 2	35
KHK7580 + KRN1493	Kyowa Kirin	Phase 2/3	38
KHK7580	Kyowa Kirin	Phase 1	29
KHK7580	Kyowa Kirin	Phase 1/2	32
KHK7580	Kyowa Kirin	Phase 3	40
KHK7580	Kyowa Kirin	Phase 3	40
Cinacalcet HCl	Kyowa Kirin	Approved	43
KHK7580 + Cinacalcet Hydrochloride	Kyowa Kirin	Phase 3	40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493	Kyowa Kirin	Phase 2	35
Paricalcitol + Calcitriol	AbbVie	Pre-clinical	18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo	AbbVie	Phase 3	40
Paricalcitol + Calcifediol	AbbVie	Approved	43
Paricalcitol + Darbepoetin alfa	AbbVie	Approved	43
Alendronate 70mg weekly	Merck	Approved	35
Etelcalcetide	Amgen	Phase 3	40
Cinacalcet + Placebo	Amgen	Phase 2	35
Cinacalcet + Placebo	Amgen	Phase 3	40
Etelcalcetide + Placebo	Amgen	Phase 1	29
Sensipar (Cinacalcet HCl)	Amgen	Phase 2	35
AMG 073 + Placebo	Amgen	Phase 3	40